Wall Street Zen Downgrades Aclaris Therapeutics Stock

Analysts lower rating on the biotech company's shares to 'sell'

Apr. 12, 2026 at 5:06am

Got story updates? Submit your updates here. ›

An extreme close-up of gears, levers, and other heavy industrial banking equipment, rendered in a high-contrast, cinematic style that conveys the institutional power and security of the financial system.As concerns mount over Aclaris Therapeutics' pipeline and finances, the company's stock faces a downgrade, exposing the complex machinery underlying the biotech industry.Malvern Today

Wall Street Zen, an equity research firm, has downgraded shares of Aclaris Therapeutics (NASDAQ: ACRS) from a 'hold' rating to a 'sell' rating in a new research report. The move comes as the company faces challenges in its pipeline of dermatology drug candidates.

Why it matters

Aclaris Therapeutics is a clinical-stage biotech focused on developing treatments for chronic inflammatory skin conditions and non-melanoma skin lesions. The downgrade from Wall Street Zen could signal broader concerns about the company's prospects and impact investor sentiment around the stock.

The details

In the research report, Wall Street Zen cited concerns about Aclaris Therapeutics' pipeline progress and financial performance. The analysts noted that the company's lead programs, including ATI-50002 for molluscum contagiosum and ATI-50003 for common warts, have faced delays in development. Additionally, Aclaris reported a wider-than-expected loss in its most recent quarterly earnings.

  • Aclaris Therapeutics stock opened at $4.04 per share on Friday, April 12, 2026.
  • The company reported its latest quarterly financial results on February 26, 2026.

The players

Wall Street Zen

An equity research firm that provides analysis and ratings on publicly traded companies.

Aclaris Therapeutics

A clinical-stage biopharmaceutical company focused on developing treatments for dermatological conditions and rare disorders.

Got photos? Submit your photos here. ›

What they’re saying

“We must downgrade Aclaris Therapeutics to a 'sell' rating due to the challenges we see in their pipeline and financial performance.”

— Wall Street Zen Analyst, Equity Research Analyst

What’s next

Investors will be closely watching Aclaris Therapeutics' upcoming pipeline updates and financial reports to gauge the company's progress in addressing the concerns raised by Wall Street Zen.

The takeaway

The downgrade from Wall Street Zen highlights the competitive and uncertain nature of the biotech industry, where even promising companies can face setbacks in drug development and financial performance. Aclaris Therapeutics will need to demonstrate clear progress in its pipeline and financial stability to regain investor confidence.